Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome

This study has been completed.
Sponsor:
Collaborator:
Pusan National University Hospital
Information provided by (Responsible Party):
Kyoo-Hyung Lee, Asan Medical Center
ClinicalTrials.gov Identifier:
NCT00732316
First received: August 8, 2008
Last updated: July 16, 2012
Last verified: July 2012